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Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory
disease of the central nervous system, manifesting clinically as optic neuritis, myelitis,
and certain brain and brainstem syndromes. Cases clinically diagnosed as NMOSD
may include aquaporin 4 (AQP4)-antibody-seropositive autoimmune astrocytopathic
disease, myelin oligodendrocyte glycoprotein (MOG)-antibody-seropositive inflammatory
demyelinating disease, and double-seronegative disease. AQP4-antibody disease
has a high female-to-male ratio (up to 9:1), and its mean age at onset of ∼40
years is later than that seen in multiple sclerosis. For MOG-antibody disease,
its gender ratio is closer to 1:1, and it is more common in children than in
adults. Its clinical phenotypes differ but overlap with those of AQP4-antibody
disease and include acute disseminated encephalomyelitis, brainstem and cerebral
cortical encephalitis, as well as optic neuritis and myelitis. Double-seronegative
disease requires further research and clarification. Population-based studies over
the past two decades report the prevalence and incidence of NMOSD in different
populations worldwide. One relevant finding is the varying prevalence observed
in different racial groups. Consistently, the prevalence of NMOSD among Whites
is ∼1/100,000 population, with an annual incidence of <1/million population.
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Among East Asians, the prevalence is higher, at ∼3.5/100,000 population, while the
prevalence in Blacks may be up to 10/100,000 population. For MOG-antibody disease,
hospital-based studies largely do not observe any significant racial preponderance
so far. This disorder comprises a significant proportion of NMOSD cases that are
AQP4-antibody-seronegative. A recent Dutch nationwide study reported the annual
incidence of MOG-antibody disease as 1.6/million population (adult: 1.3/million,
children: 3.1/million). Clinical and radiological differences between AQP4-antibody and
MOG-antibody associated diseases have led to interest in the revisions of NMOSD
definition and expanded stratification based on detection of a specific autoantibody
biomarker. More population-based studies in different geographical regions and racial
groups will be useful to further inform the prevalence and incidence of NMOSD and their
antibody-specific subgroups. Accessibility to AQP4-antibody andMOG-antibody testing,
which is limited in many centers, is a challenge to overcome. Environmental and genetic
studies will be useful accompaniments to identify other potential pathogenetic factors
and specific biomarkers in NMOSD.
Keywords: neuromyelitis optica spectrum disorder, NMOSD, AQP4, MOG, prevalence, incidence, population study,
epidemiology
INTRODUCTION
Neuromyelitis optica spectrum disorder (NMOSD) is an
uncommon inflammatory disease of the central nervous system,
with clinical features of optic neuritis, myelitis, and certain
brain, and brainstem syndromes. Although it had long been
debated whether NMOSD is a severe variant of multiple sclerosis
(MS), the discovery of NMOSD-specific aquaporin 4 (AQP4)
antibody, and the subsequent clinical, immunological, and
pathological data have established that NMOSD is indeed a
distinct entity (1–3). Currently, cases clinically diagnosed as
NMOSDmay include AQP4-antibody-seropositive autoimmune
astrocytopathic disease, myelin oligodendrocyte glycoprotein
(MOG)-antibody-seropositive inflammatory demyelinating
disease, and double-seronegative disease (4).
AQP4-antibody-seropositive NMOSD has a high female-to-
male ratio (up to 9:1) (5), and its mean age at onset is around
40 years (6, 7), older than in MS. Pathologically, it is primarily an
astrocytopathic disease rather than a demyelinating disease (3, 8).
For MOG-antibody disease, the sex ratio is close to 1:1, and it
is more common in children than in adults (9, 10). Its clinical
manifestations overlap with those of AQP4-antibody disease but
there are differences about which there is emerging consensus.
Besides optic neuritis and myelitis, its clinical phenotypes also
include acute or multiphasic disseminated encephalomyelitis
(ADEM/MDEM), brainstem and cerebral cortical encephalitis,
and cranial nerve involvement (11–14). Double (AQP4- and
MOG-antibodies)-seronegative disease is enigmatic at present
and requires further clinical and laboratory research for
specific classification.
There have been several editions of the diagnostic criteria
for NMOSD since 1999 (15, 16), with the latest being the 2015
International Panel on NMO Diagnosis (IPND) criteria (17). In
the meantime, laboratory assays for AQP4 antibody and MOG
antibody have also improved over time, with increased sensitivity
and specificity (18, 19). These factors have contributed to the
improvement in the accuracy of the diagnosis of NMOSD cases.
In this article, we review current data on the worldwide
epidemiology of NMOSD, specifically on the population-based
studies of NMOSD to determine its prevalence and incidence
among different populations and racial groups. We emphasize
that the field of NMOSD is undergoing a rapid evolution, making
epidemiological estimates tentative. Additionally, different levels
of diagnostic rigor to exclude NMOSD mimics and access to
medical care in study populations can bias the epidemiological
survey results in the disease, which makes the interpretation
and comparison of the findings in and across the studies
difficult. Nonetheless, the best known of current knowledge is
being presented.
Search Strategy and Selection Criteria
The PubMed database was searched for population-based studies
on NMOSD with prevalence data, from 1st January 2000
till 11th March 2020. A combination of the following search
terms was used: “neuromyelitis optica,” “NMO,” “NMOSD,”
“aquaporin 4,” “AQP4,” “myelin oligodendrocyte glycoprotein,”
“MOG,” “optico-spinal multiple sclerosis,” “OSMS,” “idiopathic
inflammatory demyelinating disease,” “IIDD,” “epidemiology,”
“prevalence,” “population,” and “demographic.” The reference
lists in published articles on NMOSD were also queried
to identify further studies. Additionally, recent conference
proceedings of major neurology and MS congresses, including
the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS) and the Pan-Asian Committee
for Treatment and Research in Multiple Sclerosis (PACTRIMS),
were searched for relevant abstracts where the full studies are
not yet published. Population-based studies with information on
the prevalence of NMOSD in English language were reviewed.
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The final list of publications was selected on the basis of relevance
to the topic.
Prevalence of NMOSD
The prevalence range of NMOSD is ∼0.5–4/100,000, and may
be up to 10/100,000 in certain racial groups. Nevertheless, this
prevalence range is rather small relative to that of MS, which
ranges from 1–2/100,000 in the equatorial region, to 150–
200/100,000 in Canada and northern part of Europe (20, 21).
Over the past two decades, population-based studies of
NMOSD have provided important insights into its prevalence.
The earliest population-based studies were conducted in French
West Indies (Martinique) (22, 23), Cuba (24), Denmark (25),
and Tokachi Province on Hokkaido Island in Japan (26).
Interestingly, the majority of these early studies were conducted
on island populations, which facilitate population-based studies
by providing well-delimited boundaries of the study area. Two
of the studies (Martinique and Hokkaido) (22, 23, 26) have since
been updated by the original groups of researchers.
Since 2017, several new population-based studies were
published, expanding knowledge of NMOSD in diverse
populations around the world. Inter-racial variation in
prevalence, as summarized in Table 1, is notable and consistent
across geographical regions. More recently, the Australia/New
Zealand group has also re-analyzed the data from their 2017
study (47) to provide further information with regards to the
prevalence among different racial groups in their large continent
(46). Figure 1 is a map showing population-based prevalence
studies of NMOSD around the world.
East Asians
East Asians (Japanese, Chinese, and Koreans) appear to have a
higher prevalence of NMOSD (around 3.5/100,000) as compared
to Whites and other Asian racial groups. The study in
Hokkaido, Japan recorded a prevalence of 4.1/100,000 (36),
while the Japanese nationwide survey estimated a prevalence of
3.42/100,000 (40). Meanwhile, a study conducted in the multi-
racial population in Penang Island, Malaysia showed that the
prevalence among Chinese was 3.31/100,000 (39). These results
were in line with the genetic studies that showed that Japanese
and Chinese share the same HLA risk genes for NMOSD,
namely, HLA-DPB1∗05:01 and HLA-DRB1∗16:02 (49–51). In a
very recent study from South Korea, by using a nationwide health
insurance research dataset, it was calculated that the prevalence
among Koreans was 3.56/100,000 in 2017 (48). More studies,
especially from China, Taiwan, and Hong Kong will be useful to
further inform the prevalence of NMOSD among the East Asians.
Blacks
In 1971, a study conducted in a single hospital in the sub-Saharan
African city of Ibadan (Nigeria) reported 95 cases of NMO, 22
cases of acute transverse myelitis, 11 cases of bilateral retrobulbar
neuritis, and only two cases of MS over 12 years of hospital
admissions (1957–1969) (52). During the same period, there were
nine cases of non-Nigerians with MS (in eight Europeans and
one Indian). It estimated that NMO cases made up 0.43/1000 (or
430/100,000) of the hospital population.
Population-based studies over the past two decades showed
that Blacks also have a higher NMOSD prevalence than Whites.
A study conducted in Liverpool, UK reported a prevalence rate of
1.8/100,000 among Blacks (29). The Australia/NewZealand study
estimated a prevalence rate of 1.84/100,000 in those with African
ancestry (46). The study conducted in the French Martinique
Island in the Caribbean reported a very high prevalence of
11.5/100,000 among its Black population (34), and this was the
highest prevalence reported so far. In population-based studies,
within the same localities, prevalence among Blacks is always
higher than in Whites, as seen in Cuba (24), Liverpool (UK)
(29), Olmsted county (USA) (34), Martinique Island (34), and
Australia/New Zealand (46).
As Blacks are genetically diverse, more data from different
geographical regions are needed, and especially those from the
African continent. Although no population-based studies of
NMOSD have been published from Africa, recently there have
been reports of NMOSD cases from various African countries
that are to be compiled and reported elsewhere.
Whites/Caucasians
In recent nationwide and region-wide studies, the prevalence
of NMOSD among Whites has consistently been ∼1/100,000.
The prevalence was 0.55/100,000 in Australia and New Zealand
(46, 47), 0.89/100,000 in Catalonia (38), 1.09/100,000 inDenmark
(42), and 1.04/100,000 in Sweden (43). Also recently, a re-
analysis of the data of an earlier study from South Denmark has
reported the prevalence of AQP4-antibody-positive NMOSD as
1.68/100,000, and the prevalence of the total clinical phenotype
including AQP4-antibody-negative and MOG-antibody-positive
subsets was 4.4/100,000 (25, 27).
Interestingly, the prevalence among Hungarians was slightly
higher, at 1.91/100,000 (45). This has brought up the notion of
whether there are some admixtures of Asian genes (from North
East Asia) among the Hungarians (53). Furthermore, there is
scarcity of prevalence data from Central Asia, and such data from
this region will be informative.
Other Asians
South Indians
If the 2015 IPND criteria were applied, the prevalence among
South Indians inMangalore was 0.72/100,000 (31). No cases were
found among the 10% South Indian population in Penang Island,
Malaysia (39), suggesting a low prevalence.
Austronesian Peoples
The Austronesian peoples reside in the Philippines, Malaysia,
Indonesia, the Pacific Islands (Polynesia, Micronesia, and
Hawaii), down to New Zealand, and also to the west
in Madagascar. The study conducted in the multi-racial
Penang Island, Malaysia (39) found that the prevalence of an
Austronesian group, the Malays, was ∼0.80/100,000 (this was
revised from 0.43/100,000 as reported earlier, after a new case
was diagnosed). The prevalence data from another Austronesian
group was available recently, namely, theMāoris in New Zealand,
with an estimated prevalence of 1.50/100,000 (46). Nevertheless,
in the same study, no cases of NMOSD were found among



























































et al. (2009) (24)






























(0.72 if using 2015
IPND criteria)
NR NR 27% 1.2:1
Etemadifar et al.
(2014) (32)
Isfahan, Iran 1.9 NR NR 66% 2.3:1
Kashipazha et al.
(2015) (33)













11.5 7.3 Mayo CBA 79% 8.8:1
van Pelt et al.
(2016) (35)











Tehran, Iran 0.86 NR ELISA 47% 5.1:1
Sepúlveda et al.
(2018) (38)







































































































Blacks East Asians Other
Asians/Other
Races



















Arabs: 1.09 1.16 NR 83% All females
Papp et al. (2018)
(42)





Sweden 1.04 0.79 Immunoblot
and CBA
NR 2.8:1
Kim et al. (2019)
(44)
South Korea Koreans: 2.56 7.3 CBA NA 2.37:1




1.32 CBA 83% 8.8:1
Bukhari et al. Australia and 0.55 1.84 Asians: 1.57 0.37 IF tissue >90% 6:1









Lee et al. (2020)
(48)
South Korea Koreans: 3.56 4.1–6.5 NA NA 4.7:1
*Only consider adult population. (As AQP4-antibody-positive NMOSD is rare in children, thus, if full population is considered, the prevalence will be slightly lower).
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FIGURE 1 | Map showing population-based prevalence studies of NMOSD around the world. There were eight studies in Europe, 10 in Asia, one in Oceania, and two
in the Americas (one in Cuba and one joint study in the USA and Martinique Island). Numbers given were prevalence per 100,000 population. In certain studies, the
prevalence according to racial groups was given. Adults, only adult population was studied.
the ∼295,000 Pacific Islanders (Pasifika) (46). More data from
other Austronesian groups in other localities will be useful to
clarify this.
Arabs
A study from Abu Dhabi, United Arab Emirates reported six
cases of NMOSD among its citizens, consistent with a prevalence
of 1.09/100,000 (AQP4-antibody seropositivity: 83%, all six cases
were females) (41). If only adult citizens aged ≥20 years were
considered (a total of five cases), the prevalence is higher at
1.76/100,000. Data on Arabs in other regions of Middle East and
North Africa will be very informative.
Australian Aborigines
The Australian Aborigines are one of the oldest populations
in the world, with their ancestors having migrated to Australia
around 50,000 years ago. There is evidence of some admixture
of Denisovan genes in the Aborigines (Denisovans are an extinct
species or subspecies of humans of the genus Homo). It is
interesting to note that MS rarely exists in the Aborigines (54,
55). Recent data showed that NMOSD is also rare among the
Aborigines, with a prevalence of 0.38/100,000 (46). However, the
paper cautioned whether inequality in health care accessmay lead
to this low figure.
Native Americans
MS is less common among Native Americans than in Whites
in North America. Prior to AQP4-antibody discovery, a study
conducted among the Native Canadians in Manitoba (56) found
seven cases of “MS,” of which five cases were of NMOphenotypes,
while the other two had brainstem involvement. Autopsy of one
patient showed eosinophil infiltration in the cervical cord lesion,
and retrospectively, this pathological finding suggests that this
case was likely to be NMOSD. Genetically, Native Americansmay
be more closely related to early East Asians, and thus they may
also have a higher prevalence than Whites. A re-look at these
native populations will be helpful to confirm the results, though
may be practically difficult.
Latin America
After the arrival of Europeans in the 1500’s, the indigenous
populations of Latin American had dwindled rapidly. Today,
along with the indigenous peoples, there is a large proportion of
Whites, Blacks, and mixed races in Latin America.
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In an earlier study from a tertiary hospital in Mexico City
(57), using 1999 Wingerchuk criteria, a total of 34 cases of NMO
were identified, with all patients being Mestizos (mixed race). By
calculating the ratio of MS and NMO in the hospital, and by
using the estimated MS prevalence in the country at that time,
it was extrapolated that the prevalence of NMO among Mexican
Mestizos was around 1.3/100,000. With the availability of AQP4-
antibody assays, and the newer diagnostic criteria that include
NMOSD cases, this prevalence rate is likely to be higher.
From the preliminary findings of a recent study involving
seven general hospitals in Venezuela presented at a conference
(58), it was estimated that the prevalence of NMOSD in
Venezuela was 2.2/100,000, with a female-to-male ratio of 4:1,
and again Mestizos formed the majority of those patients.
Studies from other representative populations will be useful to
further inform the prevalence of NMOSD in Latin America.
North Africa
The populations of North Africa consist mainly of Amazighs
(Berbers) and Arabs. As in Whites/Caucasian populations, there
appear to be much higher number of MS than NMOSD cases
in North Africa (59, 60). There have been no population-based
studies on NMOSD in North Africa so far. There is only one
population-based study on Arabs in theMiddle East (Abu Dhabi)
(41), and the prevalence data among Amazighs are awaited.
Incidence of NMOSD
Table 1 summarizes the incidence reported in the available
population-based studies. Among Whites, the annual incidence
of NMOSD is generally reported to be around 0.5–0.8/million
(30, 38, 42, 43). In populations with a higher prevalence, the
incidence is also higher. For instance, Blacks in Martinique have
a high prevalence of 11.5/100,000, and its incidence was also
reported to be high, at 7.3/million (34). Recently, the data from
South Korea also showed a high incidence, ranging from 4.1 to
7.3/million for the period 2013–2017 (44, 48). Other populations
with a prevalence higher than 1/100,000 also reported an
incidence higher than 1/million [for example, 1.16/million in
Arabs (41), and 1.32/million in Hungarians (45)].
A limitation regarding incidence calculation is that, if a new
antibody test becomes available in the study region, or when
there is increased awareness among clinicians, then the number
of newly diagnosed cases in that particular year will be higher,
leading to a higher incidence rate, even though the disease could
have started many years earlier in some cases. Nevertheless, if
researchers are able to calculate the incidence rates over the past
few years (e.g., past 5 years) and average them, it is likely to be
more accurate.
For pediatric NMOSD, there were two recent
nationwide/region-wide studies that reported on its incidence.
In the Danish study, the incidence of pediatric NMOSD was
calculated as 0.31/million (61). In the Taiwanese study using
the national health insurance research database, over the period
from 2011 to 2015, the average annual incidence was reported
as 1.1/million (62). Again, this higher incidence in Taiwan as
compared to Denmark is not surprising as NMOSD is more
prevalent among East Asians than Whites.
Age and Racial Differences in the Clinical
Features and Severity of NMOSD
Some studies have analyzed how the clinical features and
disability are affected by onset age and racial differences. Patients
with young-onset NMOSDweremore likely to have optic neuritis
as onset attack, while older-onset patients often developed
myelitis as the initial presentation (63). Furthermore, young-
onset patients with optic neuritis were more likely to develop
not only recurrent optic neuritis but also higher likelihood
of developing blindness, as compared to older-onset patients
with optic neuritis (63, 64). Conversely, older-onset patients
with myelitis often had poor recovery, while most young-onset
patients with myelitis recovered well without permanent motor
disability (63, 64).
There also appears to be some differences in the clinical
features of NMOSD among different races. Blacks and Asians
tended to have lower mean ages at onset than Whites (Blacks:
around 28–33 years, Asians: 35–40 years, vs. Whites: 44 years)
(63, 65). Black and Asian patients were more likely to have
brain and brainstem attacks and abnormalities on brain MRI as
compared to Whites (64, 65). Overall, the risk of relapse was
lowest in Japanese than in Whites and Blacks (63, 64).
Blacks were found to have a greater likelihood of developing
visual disability with time than Whites and Japanese (63, 64). On
the other hand, Whites had a higher probability of developing
severe motor disability or wheelchair dependence as compared
to Japanese (63). Severe attacks were more frequent in Blacks
than in Asians and Whites, and therefore Blacks were at a higher
risk of severe disability in the early course of the disease (65).
In a study from the USA, patients with African ancestry were
also found to have a higher mortality rate (15.4%) as compared
to the overall mortality rate (7.0%) (66). Nonetheless, while race
affected the clinical phenotype, age at onset, and severity of
attacks, the overall outcomes weremostly dependent on early and
effective immunosuppressive treatment (65).
MOG-Antibody-Associated Disease:
Prevalence and Incidence
After the discovery of the AQP4 antibody, a majority of NMO
cases have been found positive for this antibody. Nevertheless,
there is still a proportion of cases with an NMO phenotype that
are persistently tested negative for AQP4 antibody, despite using
the most sensitive cell-based assays available. It was later realized
that some of these AQP4-antibody-negative NMOSD cases were
in fact seropositive for MOG antibody. This so-called MOG-
antibody-associated disease consists of a significant proportion
of NMOSD cases that are AQP4-antibody seronegative, ranging
from 7 to 42% (7, 67–70).
Interestingly, for MOG-antibody-associated disease, besides
NMO phenotype, optic neuritis, and myelitis, some of these
MOG-antibody-positive cases also have clinical phenotypes
beyond the current NMOSD spectrum, such as ADEM/MDEM-
like presentation (71), cerebral cortical encephalitis (12), and
cranial nerve involvement (14). Pathologically, MOG-antibody-
associated disease is a type of demyelinating disease, as opposed
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to astrocytopathic disease seen in AQP4-antibody-positive
NMOSD (72, 73).
A recent Dutch nationwide study reported the incidence
of MOG-antibody-associated disease as 1.6/million, with
1.3/million in adults, and a higher incidence of 3.1/million in
children (74). It should be noted that this incidence rate of
1.6/million is higher than the incidence rate of 0.5–0.8/million in
NMOSD (mostly AQP4-antibody-positive) among Whites.
So far, hospital-based studies largely did not observe any
significant racial preponderance for MOG-antibody-associated
disease. For instance, in the UK cohort, the racial breakdown
was as expected in the general population (9). Nevertheless,
from the annual report of the Oxford NMO Service, there
were 145 patients with AQP4-antibody-positive NMOSD, 111
patients with MOG-antibody disease, and 28 patients who
were double-seronegative. The proportion of MOG-antibody
disease within the NMOSD spectrum was rather significant
(75). Additionally, a study from Mayo Clinic on AQP4-
and MOG-antibody testing for 15,598 patients showed higher
positivity rate for MOG antibody (1291 patients, 8.3%) than
for AQP4 antibody (387 patients, 2.3%). Of the adults, 6.5%
were MOG-antibody positive vs. 2.6% for AQP4 antibody,
while in children, 21.1% were positive for MOG antibody as
compared to 1.9% for AQP4 antibody (76). Similarly, one
study in Sri Lanka, in collaboration with the Mayo Clinic,
also reported more MOG-antibody-positive cases (126 patients)
than AQP4-antibody-positive cases (36 patients) (77). On the
other hand, MOG-antibody-associated disease was relatively
uncommon in the non-Caucasian population in Rio de Janeiro
(Brazil) (70).
The preliminary findings of a population-based prevalence
study of MOG-antibody-associated disease, jointly conducted at
TABLE 2 | Epidemiological and clinical comparison between AQP4-antibody-seropositive NMOSD, MOG-antibody disease, and MS.
AQP4-antibody disease MOG-antibody disease MS
Mean age at onset 40 years More common in children than in adults 30 years
Female:male ratio 9:1 Around 1:1 2–4:1
North–South gradient No increased prevalence with increasing
latitude
No data Increased prevalence with increasing
latitude from the equator (either
toward North or South)
Prevalence East Asians: 3.5/100,000
Whites: 1/100,000
Blacks: range from 1.8 to 10/100,000
More common in children than in adults Up to 100–200/100,000 in White
populations, but <5–50/100,000 in
many Asian and African countries
Rising in most parts of the world
Annual incidence Around 0.5–0.8/million in Whites
Higher annual incidence in
non-White populations
Dutch nationwide study: 1.6/million;
adults: 1.3/million; children: 3.1/million
More data are needed
Up to 100/million in White
populations, but was low in many
equatorial countries
Disease course Relapsing Monophasic or relapsing Relapsing, with the majority eventually
converting to a secondary
progressive disease
















Optic neuritis Unilateral/chiasmal, long (>1/2 of optic
nerve)
Unilateral/simultaneous bilateral, long;
frequent optic disc swelling (papillitis)
Unilateral, short
Myelitis Long (>3 vertebral segments) in 85%;
centrally located; affects cervical or
thoracic cord
Often long, but may be <3 vertebral
segments; gadolinium enhancement less
common than AQP4-antibody disease;




Attack severity Moderate to severe Mild to moderate Mild to moderate
Recovery Variable, but commonly poor Fair to good Fair to good
Disability Attack-related Attack-related Mainly due to progression
Pathology Astrocytopathy Demyelination Demyelination
Treatment Immunosuppressants; some MS drugs
may be harmful
Consider immunosuppressants if
recurrent; some MS drugs may be
ineffective
MS disease-modifying drugs
ADEM/MDEM, acute disseminated encephalomyelitis/multiphasic disseminated encephalomyelitis; AQP4, aquaporin 4; MOG, myelin oligodendrocyte glycoprotein; MS, multiple
sclerosis; NMOSD, neuromyelitis optica spectrum disorder.
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Olmsted county (USA) and Martinique Island, were recently
presented at a conference (ECTRIMS 2019) (78). In Olmsted
county, the prevalence was calculated to be 3.42/100,000, with an
incidence of 2.39/million, while atMartinique, the prevalence was
1.6/100,000, with an incidence of 1.12/million.
In the Catalonia NMOSD prevalence study, 12% of cases
were MOG-antibody-positive (38). However, the cases in this
study were required to strictly fulfill the 2015 IPND criteria, and
thus only those with an NMO phenotype were analyzed (The
prevalence of MOG-antibody-positive NMOwas calculated to be
0.11/100,000.). Needless to say, if MOG-antibody-positive cases
with optic neuritis alone or myelitis alone and those with ADEM-
like presentation are included, the prevalence of MOG-antibody
disease is likely to be higher.
More data from different geographical areas are clearly in
need to further inform about the prevalence and incidence of
MOG-antibody-associated disease.
Some demographic and epidemiological data and clinical
features of AQP4-antibody-positive NMOSD and MOG-
antibody-associated disease in comparison with MS are shown
in Table 2.
CONCLUSION
There appears to be varying prevalence rates of NMOSD, most
cases of which are AQP4-antibody-positive cases, among the
different racial groups worldwide, with East Asians and Blacks
having a higher prevalence than Whites. In most regions, these
prevalence rates are lower than that of MS. In AQP4-antibody-
positive NMOSD, female preponderance is definite (up to 90%)
and the majority of the cases are adults. Moreover, the clinical
features of NMOSD and disability accrual may be influenced by
onset age and race. The data suggest that certain genetic and
environmental factors associated with race may be involved in
the pathogenesis of NMOSD. More well-designed population-
based and longitudinal studies in different geographical areas
and racial groups will be useful to clarify the issue, and to
shed new lights onto this unique neuroinflammatory disease.
Among AQP4-antibody-negative NMOSD, some patients are
MOG-antibody-positive, and unlike AQP4-antibody-positive
NMOSD, males, and females are equally affected by MOG-
antibody-associated disease and the prevalence may be higher
in children than in adults. However, the prevalence data of
MOG-antibody-associated disease including the ones with an
NMOSD phenotype are still insufficient and being accumulated.
Accessibility to AQP4-antibody and MOG-antibody testing,
which is currently limited in many regions, is a challenge
to overcome.
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